Galapagos and CHDI Enter new Collaboration Agreements
News Oct 30, 2008
Galapagos NV and CHDI Foundation, Inc., a non-profit organization pursuing treatments for Huntington's disease (HD), announced new collaboration agreements focused on developing assays for drug discovery and evaluating known compounds as potentially new therapeutic approaches for HD. Total value of the contracts for Galapagos is $1 million (€0.8 million) over 1.5 years.
Galapagos' service division, BioFocus DPI, will develop a high throughput screening assay in mouse neurons that will enable the identification of compounds that prevent neuronal dysfunction associated with HD. BioFocus DPI will also make use of its expertise in profiling and assay development to evaluate known compounds inhibiting certain enzymes playing key roles in HD. These new programs continue the collaboration started in August 2005.
"The new programs initiated with CHDI demonstrate how innovative BioFocus DPI is in its drug discovery expertise," said Onno van de Stolpe, CEO of Galapagos. "With its growing list of patient organizations in the client base, our service division continues to build on its reputation for high quality drug discovery."
"Galapagos demonstrated its capabilities in our target discovery collaboration, which encouraged us to choose BioFocus DPI for these new programs," added Ignacio Munoz, Vice-President of Biology at CHDI.
New Chemical Synthesis Process: Synergy of Two Catalysts in One FlaskNews
Researchers report the one-step synthesis of a ketone from an aldehyde by the combination of thiazolium N-heterocyclic carbene and palladium/bisphosphine catalysts in one flask. The two catalysts function in a synergistic manner. This study is expected to lead to new synthesis processes of precursor compounds for medications.READ MORE
Synthesis of Drug-Like Molecules Simplified Using New Cross-Coupling MethodNews
Researchers have designed a new molecule-building method. The technique, described recently in the journal Science, paves the way toward other new chemical reactions and facilitates the synthesis of pharmaceutically-relevant molecules.READ MORE
Domainex Appoints Dr Bodo Spori as Head of Business Development for EuropeNews
Domainex Ltd, a privately-owned drug discovery services company, is pleased to announce the appointment of Dr Bodo Spori as Head of Business Development for Europe.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Pharmacy and Clinical Research
Jul 16 - Jul 17, 2018
6th Annual Congress on Biology and Medicine of Molecules
Sep 17 - Sep 18, 2018